Drug induced gingival hyperplasia Ilaclarla olusan gingival hiperplazi
SENDROM, cilt.11, sa.7, ss.22-32, 1999 (Scopus)
- Yayın Türü: Makale / Kısa Makale
- Cilt numarası: 11 Sayı: 7
- Basım Tarihi: 1999
- Dergi Adı: SENDROM
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.22-32
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Drug-induced gingival enlargement was described more than 50 years ago. The drugs which causes enlargement in gingiva are usually three group divies; anticonvulsants, immunosuppressant, calcium channel-blocking agents. Despite extensive study of drug-induced gingival enlargement, the mechanism by which chemical substances initiate tissue overgrowth is poorly understood, and consequently, treatment modalities are often empirical and the results are equivocal. In drug induced gingival enlargement, the clinical situation is often clouded by the presence of gingival inflammation and the medical status of the patient. Treatment outcomes are often unpredictable because it may not be possible to discontinue the inductive drug. The clinician should make every effort to achieve optimal oral health in affected patients, and close medical/dental coordination is essential. When therapy is initiated using a drug capable of inducing gingival overgrowth, the patient should be referred by physician to the dentist or perodontist for baseline evaluation and elimination or control of local etiologic factors. The patients should be managed with a rigorous oral hygiene regimen, such as more frequent dental visits for professional prophylaxis and instruction in meticulous oral hygiene, including the use of antimicrobial mouthrinses when indicated. One time or periodic surgical intervention may be necessary, especially if the causative drug cannot be discontinued. This article reviews the literature regarding drug-induced gingival enlargements, and proposes a logical approach to managing patients with this condition.